NL-OMON52744招募中不适用
A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute myeloid leukemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantation. - WiNK
Glycostem Therapeutics0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •To be eligible to participate in this trial, subjects must meet all of the
- •following eligibility criteria:
- •1. Male or female subjects >= 18 years old
- •2. Subjects with a diagnosis of AML and related precursor neoplasms according
- •to the World Health Organization (WHO) 2016 classification (excluding acute
- •promyelocytic leukaemia), including secondary AML after an antecedent
- •haematological disease (e.g. myelodysplastic syndrome) and therapy-related AML
- •3. a. For cohorts A1, A2, A3, A5 (and cohort B if applicable): Subjects who
- •have achieved morphologic CR, including CRi, and complete clinical remission,
- •with MRD documented at screening, after one or two courses of remission
- •induction chemotherapy and who have completed consolidation chemotherapy or who
- •achieved morphologic CR with documented MRD with hypomethylating agents (HMAs)
- •or other relevant appropriate therapies (e.g. HMAs in combination with
- •venetoclax)
- •b. For cohort A4 (and cohort B if applicable): Subjects with newly diagnosed
- •AML who have achieved morphologic CR, including CRi while undergoing
- •azacitidine-venetoclax standard of care treatment, and who are MRD-positive on
- •the 28th day (+/- 7 days) of at least treatment cycle 3 or later cycles (>=3)
- •4.Subjects who are currently (at the time of screening) not proceeding to
- •allo-HSCT, i.e.:
- •a. Subjects who have a contraindication for allo-HSCT (e.g. age > 75 years old,
- •diffusing capacity of the lung for carbon monoxide [DLCO] < 60%, left
- •ventricular ejection fraction [LVEF] < 40%, liver cirrhosis, creatinine
- •clearance < 30 mL/min, hematopoietic stem cell transplantation-specific
- •comorbidity index [HCT-CI] >= 5); or
- •b. Subjects who have no contraindication for allo-HSCT but do not proceed:
- •i. By personal choice; or
- •ii. Because there is no compatible donor expected to be available in a timely
- •iii. Due to unfavorable patient-specific risk-benefit assessment discussed
- •between the treating physician and the patient and his/her close relatives.
- •Factors taken into consideration include the disease-related risk (risk of
- •relapse, toxicity or other treatment options if any), the patient-related risk
- •(age, comorbidities including the HCT-CI score) and the curative potential of
- •allo-HSCT versus toxicity (treatment intensity, graft versus leukemia effect,
- •non-relapse mortality risk) (Muller and Muller-Tidow 2015)
- •5. Life expectancy >= 6 months at screening
- •6. Adequate renal and hepatic functions within 14 days of trial screening,
- •unless clearly disease-related, as indicated by the following laboratory values:
- •a. Serum creatinine <= 3 times the upper limit of normal (ULN) and estimated
- •glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m2
- •b. Serum total bilirubin < 2.0 mg/dL, unless due to Gilbert*s syndrome
- •c. Alanine transaminase (ALT) <= 2.5 x ULN
- •7. Karnofsky Status >= 50%
- •8.Seropositivity to Epstein-Barr virus (EBV)
- •9. Male subjects with partners who are women of childbearing potential must use
- •an effective contraceptive method during the trial and for a minimum of 6
- •months after trial treatment, or have undergone successful vasectomy at least 6
- •months prior to entry into the trial (confirmed by semen analysis)
- •10. Female subjects of childbearing potential must have a negative serum
- •pregnancy test at screening and agree to use an effective contracept
排除标准
- •Subjects who meet any of the following criteria at screening will be excluded
- •from trial entry:
- •1. Subjects having received prior allo- HSCT
- •2. Subjects with acute promyelocytic leukaemia
- •3. Diagnosis of any previous or concomitant malignancy is an exclusion
- •criterion, except when the subject completed treatment (chemotherapy and/or
- •surgery and/or radiotherapy) with curative intent for this malignancy at least
- •6 months prior to enrolment
- •4. Blast crisis of chronic myeloid leukaemia
- •5. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled
- •diabetes, uncontrolled infection, hypertension active or controlled infection),
- •including abnormal laboratory values that could compromise compliance with the
- •trial protocol or cause unacceptable safety risks.
- •6. Known allergy to any of the components of oNKord® (e.g., dimethyl sulfoxide
- •[DMSO]) or to any of the drugs to be administered in the preparative regimen to
- •oNKord® infusion
- •7. For cohorts A1, A2, A3, A5 (and cohort B if applicable): contraindication to
- •any of the drugs to be administered in the lymphodepleting conditioning
- •regimen. This includes Cy, Flu, and medications associated with prophylaxis of
- •8. Cardiac dysfunction as defined by:
- •a. Myocardial infarction within the last 3 months of trial entry, or
- •b. Reduced left ventricular function with an ejection fraction < 40% as
- •measured by multi-gated acquisition (MUGA) scan or echocardiogram (echo) within
- •28 days before screening, or
- •c. Unstable angina, or
- •d. New York Heart Association (NYHA) Class IV congestive heart failure, or
- •e. Unstable cardiac arrhythmiase trial
- •9. Pulmonary dysfunction as defined by oxygen saturation < 90% on room air.
- •Pulmonary function test (PFT) is required only in the case of symptomatic or
- •prior known impairments within 28 days before screening - with pulmonary
- •function < 50% corrected (DLCO) and forced expiratory volume in 1 second (FEV1)
- •10. Major surgery within 4 weeks prior to screening or a major wound that has
- •not fully healed
- •11. Vaccination with live, attenuated vaccines within 4 weeks prior to screening
- •12. Subjects must be able to be off prednisone or other immunosuppressive
- •medications for concomitant disease for at least 3 days prior to the:
- •a. Start of the Cy/Flu regimen in cohorts A1, A2, A3, A5 (and cohort B if
- •applicable)
- •b. First oNKord® infusion in cohort A4 (and cohort B if applicable)
- •13. History of stroke or intracranial haemorrhage within 6 months prior to
- •14. Active infections (viral, bacterial or fungal) that requires specific
- •therapy. Acute anti-infectious therapy must have been completed within 14 days
- •prior to trial treatment
- •15. History of human immunodeficiency virus (HIV) or active infection with
- •hepatitis B virus (HBV) or hepatitis C virus (HCV)
- •16. a. For cohorts A1, A2, A3, A5 (and cohort B if applicable): Subjects who
- •are undergoing or will be undergoing chemotherapy (including HMAs), radiation
- •therapy, targeted therapy or immunotherapy that cannot be finished or stopped
- •at least 1 week prior to initiating the Cy/Flu conditioning regimen
- •b. For cohort A4 (and cohort B if applicable): Subjects who are undergoing or
- 另有 2 项未显示
研究者
相似试验
进行中（未招募）
1 期
A trial to evaluate the safety and efficacy of oNKord® in participants with acute myeloid leukaemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantatioEUCTR2019-003686-17-NLGlycostem Therapeutics BV40
进行中（未招募）
1 期
A trial to evaluate the safety and efficacy of oNKord® in participants with acute myeloid leukaemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantatioEUCTR2019-003686-17-DEGlycostem Therapeutics BV40
进行中（未招募）
1 期
A trial to evaluate the safety and efficacy of oNKord® in participants with acute myeloid leukaemia who are in complete morphologic remission with measurable residual disease and without a strong indication for stem cell transplantation.acute myeloid leukaemiaEUCTR2019-003686-17-FRGlycostem Therapeutics BV33
进行中（未招募）
1 期
A study to determine how the drug(ATM-AVI) is moved in your body and whether the drug is safe and tolerable for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adultsEUCTR2015-002726-39-DEPfizer Inc.40
进行中（未招募）
1 期
A study to determine how the drug(ATM-AVI) is moved in your body and whether the drug is safe and tolerable for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adultsComplicated Intra-Abdominal Infections (cIAIs) in hospitalized adultsEUCTR2015-002726-39-ESAstraZeneca AB40